All In Biotech

Drug Trial Radar · NCT06131983

Study of SRP-1001 in Adult and Adolescent Participants With Facioscapulohumeral Muscular Dystrophy Type 1

A Phase 1/2a Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARO-DUX4 (SRP-1001) in Adult Patients and Adolescent Patients With Facioscapulohumeral Muscular Dystrophy Type 1

Last checked: Nov 20, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Enrolling by invitation

Status

Enrolling by invitation

Enrollment

60

Planned (sponsor's estimate)

Start

Jun 19, 2024

Primary completion

Dec 31, 2028

Study completion Dec 31, 2028

Sponsor

Lead sponsor
Sarepta Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Nov 15, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 16 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics of SRP-1001 in participants with facioscapulohumeral muscular dystrophy Type 1 (FSHD1). In Part 1 of the study, participants will receive one dose of SRP-1001 or placebo. In Part 2 of the study, participants will receive 4 doses of SRP-1001 or placebo. Participants who complete Part 1 will have the option to re-screen and re-randomize into Part 2. All participants will undergo pre- and post-dose magnetic imaging resonance (MRI)-guided muscle biopsies (a total of 2 biopsies). Participants who complete Part 1 and enroll in Part 2 will be required to undergo an additional screening biopsy. Participants completing Part 1 or Part 2 may have the option to continue to receive drug in an open-label extension study or may be eligible to participate in later-stage clinical studies.

Conditions

  • Muscular Dystrophy, Facioscapulohumeral

Interventions

  • SRP-1001 for InjectionDrug

    Single or multiple doses of SRP-1001 by intravenous (IV) infusion

  • PlaceboDrug

    Calculated volume to match active treatment by IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment-Emergent Adverse Events Over Time Through End of StudyTime frame: Part 1: Up to Day 90; Part 2: Up to Day 360

Locations

16 sites in 7 countries. Site status is shown where the registry gives one.

  • Liverpool Hospital

    Liverpool, New South Wales, Australia

  • Wesley Research Institute

    Auchenflower, Queensland, Australia

  • Sunshine Coast University Hospital

    Birtinya, Queensland, Australia

  • Alfred Health

    Melbourne, Victoria, Australia

  • University of Calgary

    Calgary, Alberta, Canada

  • University of Alberta

    Edmonton, Alberta, Canada

  • McGill University

    Montreal, Quebec, Canada

  • Universitätsklinikum München

    München, Germany

  • Neurologische Universitätsklinik Am Rku

    Ulm, Germany

  • Centro Clinico Nemo Milann

    Milan, Italy

  • Fondazione Policlinico Universitario A. Gemelli

    Roma, Italy

  • Centre For Human Drug Research

    Leiden, Netherlands

  • New Zealand Clinical Research

    Auckland, New Zealand

  • Hospital Universitario Vall d'Hebron

    Barcelona, Spain

  • Hospital Universitario Ramon y Cajal

    Madrid, Spain

  • Hospital Universitari l Politecnic La Fe de Valencia

    Valencia, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.